Viracta Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.viracta.com

Safety Score

Market Cap $6.76M
Debt $33.82M
Cash $13.13M
EV $27.46M
FCF -$34.80M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$43.29M
EBIT	-$47.21M
ROA	-215%
FCF	-$34.80M
Equity	-$6.62M
Growth Stability	1
PE	-0.16
PB	-1.02
P/FCF	-0.19
Price/Cash	1.94
Debt/Equity	-5.11
Debt/FCF	-0.97
Sales CAGR	-1%
Equity CAGR	16%
Earnings Growth YoY	-16%
Earnings Growth QoQ	7%

Equity CAGR 5Y	-17%
Equity CAGR 3Y	-69%
Market Cap	$6.76M
Assets	$21.96M
Total Debt	$33.82M
Cash	$13.13M
Shares Outstanding	39.43M
EV	27.46M
Safety Score	40%
Working Capital	-6.77M
Current Ratio	0.76
Shares Growth 3y	5%
Equity Growth QoQ	-348%
Equity Growth YoY	-122%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

SEC Filings

Direct access to Viracta Therapeutics, Inc. (VIRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Viracta Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Viracta Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Viracta Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Viracta Therapeutics, Inc..

Years

Calculation mode

= -$348M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$348M
DCF		-$32M	-$29M	-$26M	-$24M	-$22M	-$20M	-$18M	-$16M	-$15M	-$13M	-$134M
Value	-$348M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-1K%	-1K%	-5K%	-11K%	-1K%	-18K%	-	-	-	-
ROA	-	-84%	-100%	-168%	-63%	-93%	-105%	-53%	-89%	-215%
ROE	-	-181%	-165%	-667%	-85%	-108%	-122%	-81%	-279%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-0.25	-0.7	-0.63	-0.97
Debt over Equity	0.29	0.16	0.33	1.85	0.2	0.41	0.05	0.41	1.38	-5.11
Growth Stability	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.97)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-5.11)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-17%	-74%	-65%	775%	-94%	-	-	-	-
Earnings YoY growth	-	4%	-7%	-25%	-12%	-7%	431%	-57%	4%	-
Equity YoY growth	-	-23%	2%	-81%	590%	-28%	373%	-35%	-70%	-17%
FCF YoY growth	-	-	-	-	-	-	-11%	86%	13%	-